vs
Side-by-side financial comparison of AdvanSix Inc. (ASIX) and Doximity, Inc. (DOCS). Click either name above to swap in a different company.
AdvanSix Inc. is the larger business by last-quarter revenue ($359.9M vs $185.1M, roughly 1.9× Doximity, Inc.). Doximity, Inc. runs the higher net margin — 33.3% vs -0.8%, a 34.0% gap on every dollar of revenue. On growth, Doximity, Inc. posted the faster year-over-year revenue change (9.8% vs 9.4%). Over the past eight quarters, Doximity, Inc.'s revenue compounded faster (25.2% CAGR vs 3.4%).
AdvanSix Inc. is an American chemical company that produces nylon 6 and related chemicals such as caprolactam and ammonium sulfate fertilizers. It operated as Honeywell's Resins and Chemicals division until 2016, when it was spun off as a separate company. The unit accounted for 3 percent of Honeywell's sales at the time. For 2019, revenue is estimated at $1.4 billion. The company traces its lineage to the H. W. Jayne Company, established 1884 in Frankford, Pennsylvania.
Doximity is an online networking service for medical professionals. Launched in 2010, the platform offers its members curated medical news, telehealth tools, and case collaboration.
ASIX vs DOCS — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $359.9M | $185.1M |
| Net Profit | $-2.8M | $61.6M |
| Gross Margin | 7.6% | 89.9% |
| Operating Margin | -0.7% | 38.9% |
| Net Margin | -0.8% | 33.3% |
| Revenue YoY | 9.4% | 9.8% |
| Net Profit YoY | -892.9% | -18.1% |
| EPS (diluted) | $-0.11 | $0.31 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $359.9M | $185.1M | ||
| Q3 25 | $374.5M | $168.5M | ||
| Q2 25 | $410.0M | $145.9M | ||
| Q1 25 | $377.8M | $138.3M | ||
| Q4 24 | $329.1M | $168.6M | ||
| Q3 24 | $398.2M | $136.8M | ||
| Q2 24 | $453.5M | $126.7M | ||
| Q1 24 | $336.8M | $118.1M |
| Q4 25 | $-2.8M | $61.6M | ||
| Q3 25 | $-2.6M | $62.1M | ||
| Q2 25 | $31.4M | $53.3M | ||
| Q1 25 | $23.3M | $62.5M | ||
| Q4 24 | $352.0K | $75.2M | ||
| Q3 24 | $22.3M | $44.2M | ||
| Q2 24 | $38.9M | $41.4M | ||
| Q1 24 | $-17.4M | $40.6M |
| Q4 25 | 7.6% | 89.9% | ||
| Q3 25 | 6.8% | 90.3% | ||
| Q2 25 | 14.3% | 89.2% | ||
| Q1 25 | 14.2% | 89.5% | ||
| Q4 24 | 3.4% | 91.6% | ||
| Q3 24 | 14.4% | 90.0% | ||
| Q2 24 | 17.9% | 89.3% | ||
| Q1 24 | 0.9% | 89.4% |
| Q4 25 | -0.7% | 38.9% | ||
| Q3 25 | -0.9% | 37.8% | ||
| Q2 25 | 7.7% | 37.4% | ||
| Q1 25 | 7.7% | 35.2% | ||
| Q4 24 | -3.9% | 47.4% | ||
| Q3 24 | 7.5% | 38.8% | ||
| Q2 24 | 11.5% | 36.4% | ||
| Q1 24 | -7.0% | 35.5% |
| Q4 25 | -0.8% | 33.3% | ||
| Q3 25 | -0.7% | 36.8% | ||
| Q2 25 | 7.7% | 36.5% | ||
| Q1 25 | 6.2% | 45.2% | ||
| Q4 24 | 0.1% | 44.6% | ||
| Q3 24 | 5.6% | 32.3% | ||
| Q2 24 | 8.6% | 32.7% | ||
| Q1 24 | -5.2% | 34.4% |
| Q4 25 | $-0.11 | $0.31 | ||
| Q3 25 | $-0.10 | $0.31 | ||
| Q2 25 | $1.15 | $0.27 | ||
| Q1 25 | $0.86 | $0.31 | ||
| Q4 24 | $0.02 | $0.37 | ||
| Q3 24 | $0.82 | $0.22 | ||
| Q2 24 | $1.43 | $0.21 | ||
| Q1 24 | $-0.65 | $0.20 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $19.8M | $64.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $815.2M | $979.3M |
| Total Assets | $1.7B | $1.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $19.8M | $64.8M | ||
| Q3 25 | $23.7M | $169.2M | ||
| Q2 25 | $18.4M | $137.3M | ||
| Q1 25 | $8.3M | $209.6M | ||
| Q4 24 | $19.6M | $165.3M | ||
| Q3 24 | $17.3M | $184.2M | ||
| Q2 24 | $12.1M | $111.4M | ||
| Q1 24 | $20.6M | $96.8M |
| Q4 25 | $815.2M | $979.3M | ||
| Q3 25 | $818.2M | $1.1B | ||
| Q2 25 | $823.7M | $1.0B | ||
| Q1 25 | $794.4M | $1.1B | ||
| Q4 24 | $774.6M | $1.0B | ||
| Q3 24 | $766.4M | $961.2M | ||
| Q2 24 | $746.6M | $913.6M | ||
| Q1 24 | $713.2M | $901.4M |
| Q4 25 | $1.7B | $1.2B | ||
| Q3 25 | $1.7B | $1.3B | ||
| Q2 25 | $1.6B | $1.2B | ||
| Q1 25 | $1.6B | $1.3B | ||
| Q4 24 | $1.6B | $1.2B | ||
| Q3 24 | $1.5B | $1.1B | ||
| Q2 24 | $1.5B | $1.1B | ||
| Q1 24 | $1.5B | $1.1B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $63.7M | $60.9M |
| Free Cash FlowOCF − Capex | $36.1M | — |
| FCF MarginFCF / Revenue | 10.0% | — |
| Capex IntensityCapex / Revenue | 7.7% | — |
| Cash ConversionOCF / Net Profit | — | 0.99× |
| TTM Free Cash FlowTrailing 4 quarters | $6.4M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $63.7M | $60.9M | ||
| Q3 25 | $26.6M | $93.9M | ||
| Q2 25 | $21.1M | $62.1M | ||
| Q1 25 | $11.4M | $98.5M | ||
| Q4 24 | $64.2M | $65.2M | ||
| Q3 24 | $57.3M | $68.3M | ||
| Q2 24 | $50.2M | $41.2M | ||
| Q1 24 | $-36.2M | $63.9M |
| Q4 25 | $36.1M | — | ||
| Q3 25 | $66.0K | — | ||
| Q2 25 | $-7.2M | — | ||
| Q1 25 | $-22.6M | — | ||
| Q4 24 | $29.8M | — | ||
| Q3 24 | $26.8M | — | ||
| Q2 24 | $16.7M | — | ||
| Q1 24 | $-71.6M | — |
| Q4 25 | 10.0% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | -1.7% | — | ||
| Q1 25 | -6.0% | — | ||
| Q4 24 | 9.1% | — | ||
| Q3 24 | 6.7% | — | ||
| Q2 24 | 3.7% | — | ||
| Q1 24 | -21.3% | — |
| Q4 25 | 7.7% | — | ||
| Q3 25 | 7.1% | — | ||
| Q2 25 | 6.9% | — | ||
| Q1 25 | 9.0% | 0.0% | ||
| Q4 24 | 10.4% | 0.0% | ||
| Q3 24 | 7.7% | 0.0% | ||
| Q2 24 | 7.4% | 0.0% | ||
| Q1 24 | 10.5% | 0.0% |
| Q4 25 | — | 0.99× | ||
| Q3 25 | — | 1.51× | ||
| Q2 25 | 0.67× | 1.16× | ||
| Q1 25 | 0.49× | 1.58× | ||
| Q4 24 | 182.29× | 0.87× | ||
| Q3 24 | 2.57× | 1.55× | ||
| Q2 24 | 1.29× | 1.00× | ||
| Q1 24 | — | 1.57× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ASIX
| Plant Nutrients | $140.0M | 39% |
| Chemical Intermediates | $92.8M | 26% |
| Caprolactam | $64.4M | 18% |
| Nylon Resins | $62.8M | 17% |
DOCS
| Subscription | $175.4M | 95% |
| Service Other | $9.7M | 5% |
